Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.

ABSTRACT:

Objective

O6methylguanine-DNA methyltransferase (MGMT) promoter methylation is a biomarker widely used to predict the sensitivity of IDH-wildtype glioblastoma to temozolomide therapy. Given that the IDH status has critical effects on the survival and epigenetic features of glioblastoma, we aimed to assess the role of MGMT promoter methylation in IDH-mutant glioblastoma.

Methods

This study included 187 IDH-mutant glioblastomas and used 173 IDH-wildtype glioblastomas for comparison. Kaplan-Meier curves and multivariate Cox regression were used to study the predictive effects.

Results

Compared with IDH-wildtype glioblastomas, IDH-mutant glioblastomas showed significantly higher (P < 0.0001) MGMT

SUBMITTER: Chai R 

PROVIDER: S-EPMC7877176 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature